Shivam Singh ^* Sunita Kularia Shivakshi Shukla Mithilesh Singh Manish Kumar Ashish Kumar Sharma

• Institute of Pharmacy, NIMS University, Jaipur, India

Asthma is a perpetual chronic inflammatory respiratory condition characterised by airway constriction, smooth muscle spasm, and severe morbiditysymptoms primarily related to narrowing of the airways brought on by smooth muscle contraction.It affects around 300 million people globally, with children being especially vulnerable. Despite its worldwide effect, the invention of innovative asthma medicines has been slow over the last five decades, leaving significant unmet requirements in asthma care. Although intriguing medicines have demonstrated efficacy in animal models, many fail to fulfil safety and effectiveness requirements in human trials, highlighting the critical need for more predictive models that better transfer to human results.It is a significant medical burden that affect up to 300 million people globally, with children being particularly affected. There is still an immense amount of unmet medical demand in the asthma sector.Over the past half a century very few novel medications have reached the clinic; many that show promise in preclinical animal models of asthma fail to meet safety and efficacy criteria when tested in people. There is a need to develop more predictive models and tools based on the most recent developments as a result of the inability to effectively transfer promising potential therapies from animal models to humans and concerns about the value of in vivo probes.This comprehensive review investigates the mechanisms and efficacy of anti-asthmatic drugs using both genetic and conventional animal models. Both genetic and traditional models of anti-asthmatic agents, their characteristics, and their significance are summarized as: In-Vitro Animal Models: